The landscape of obesity and cardiometabolic disease management is on the cusp of a profound transformation, driven by the emergence of a new generation of oral therapies. For years, the remarkable efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss and glycemic control has been inextricably linked to injectable formulations, creating a market dominated by medications like semaglutide (Wegovy) and tirzepatide (Zepbound). However, the imminent approva